Gd dtpa

Radiography: Routine radiographic examination consisting of standing weight-bearing postero-anterior and lateral views with the knee in 30° flexion [28 ] were obtained in all patients at baseline.
MRI consisted of the following sequences: Sagittal STIR and sagittal and axial T1-weighted sequences before contrast. Following intravenous administration of Gadolinium contrast (Gd-DTPA, 0.2 mmol/ml, GE Healthcare AS, Oslo, Norway) using 0.1 mmol/kg with a maximum of 10 mmol DCE-MRI was obtained using a sagittal T1-weighted spoiled gradient echo sequence with four sagittal slices every 5 s with 50–65 repetitions, repetition time (TR) = 50.2 ms, echo time (TE) = 4.1 ms, field of view (FOV) = 16 cm, slice thickness (ST) = 4 mm, matrix = 128 × 128, flip angle 30° and acquisition time (AT) 4.2–5.4min. Finally, sagittal and axial T1 FS post-contrast sequences were performed using the following parameters: TR = 860 ms, TE = 20 ms, FOV = 16 cm, ST = 4.0 mm, interslice gap (IG) = 0.8 mm, matrix = 512 × 512, total AT 7.2min. DCE-MRIs were missing in 6 of 44 examinations for technical reasons and follow-up analyses could therefore not be performed in 5 patients.
Details of the MRI protocol are described in an additional file (see Additional file 1).

Upper abdominal contrast-enhanced CT or MRI scans were carried out every month for the first 3 months post-operatively. If no tumor residue or tumor recurrence was detected, a re-examination was carried out every 3-6 months (CT: HiSpeed or LightSpeed QX/i, GE Medical Systems; Milwaukee, WI; contrast agent: Ultravist 300 [injection speed was fixed as 3ml/s]; Schering, Berlin, Germany; MRI: Discovery MR750 3.0T; GE Medical Systems; contrast agent: Gd-DTPA [injection speed was fixed to 3ml/s]; GE Healthcare, IDA Business Park Carrigtohill, Ireland).